An indazole derivative, YC-1, was identified in this study to be capable of reversibly and effectively inhibiting proliferation of rat AIO vascular smooth-muscle cells (VSMCs) in vitro. YC-1 (1-100 1uM) dose-dependently inhibited [3H]thymidine incorporation into DNA in rat AlO VSMCs that were synchronized by serum depletion and then restimulated by addition of 10 % foetal calf serum (FCS), whereas FCS-induced [3H]thymidine incorporation into rat synchronized endothelial cells was unaffected by this agent. The dose of YC-1 required to cause inhibition of FCS-induced proliferation was similar to that necessary for the formation of cellular cyclic GMP (cGMP). Guanylate cyclase activity in soluble fractions of VSMCs was activated by (1-100 ,uM), whereas cGMP-specific phosphodiesterase activity was unaffected by this compound. The anti-proliferative effect of YC-1 was mimicked by 8-bromo-cGMP, a membrane-permeable cGMP analogue, and was antagonized by KT 5823 (0.2,M), a selective inhibitor of protein kinase G. The anti-proliferative
INTRODUCTION
Proliferation of vascular smooth-muscle cells (VSMCs) is a prominent feature of vascular response to mechanical injury [1, 2] . Abnormal proliferation of VSMCs is a major component of vascular disease, including atherosclerosis, vascular rejection and restenosis after angioplasty [3, 4] . Therefore modulation of proliferation has critical therapeutic implications for vascular disease. An important therapeutic aim is inhibition of VSMC proliferation without interfering with endothelial or other cell proliferation. Theoretically, a selective inhibitor of VSMC proliferation is therefore required [5] . Several agents that suppress VSMC proliferation have already been identified: prostaglandins E1, E2 [6, 7] , heparin [8] , interferon a [9] , f-transforming growth factor [10] and protein kinase C activator [11] . However, no significant inhibition of atherosclerosis or restenosis has been achieved with the above agents [5] .
Much of the work involving inhibitors of VSMC proliferation has been carried out on VSMCs in culture. This technique is ideally suited to the study of action mechanisms of inhibitors and the cell cycle. A1O cells, isolated and characterized by Kimes and Brandt [12] from rat aorta, have many of the properties of smooth-muscles cells in culture. These cells have some advantages over primary cultured cells, i.e. flexibility in handling and morphological and biochemical stability after multiple passages [13] . In our studies, the characteristics of stimulation of DNA effect of YC-1 was also antagonized by Methylene Blue (50 ,uM), a guanylate cyclase inhibitor, and was potentiated by 3-isobutyll-methylxanthine (500 ,uM), a phosphodiesterase inhibitor. These results verified that YC-1 is a direct soluble guanylate cyclase activator in A10 VSMCs, and the anti-proliferative effect of YC-1 is mediated by cGMP. YC-l still inhibited FCS-induced DNA synthesis even when added 10-18 h after restimulation of the serum-deprived A1O VSMCs with 10 % FCS. Flow cytometry in synchronized populations revealed an acute blockage of FCSinducible cell-cycle progression at a point in the GJ/S-phase in YC-1 (100 1,M)-treated cells. The inhibition of proliferation by YC-1 was demonstrated to be independent of cell damage, as documented by several criteria of cell viability. In conclusion, YC-1 reversibly and effectively inhibited the proliferation of VSMCs, suggesting that it has potential as a therapeutic agent in the prevention of vascular diseases.
synthesis by mitogens and the proliferative properties of serum remained stable from passage 16 through to passage 32.
It has recently been discovered that NO and nitrovasodilators have an inhibitory effect on the proliferation of VSMCs [14, 15] by a cyclic GMP (cGMP)-mediated mechanism. In a large-scale screening test, we found that 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (YC-1), an indazole derivative (Figure 1 ), exerted vasorelaxing effects in rat aorta as well as anti-aggregatory effects in platelets, both of which protect the vascular wall against arteriosclerotic changes. The vasorelaxation and antiaggregatory effects of YC-1 were mediated by a cGMP-controlled pathway [16] . [19, 20] . The experiments were terminated by washing cells with KHS, precipitation of acidinsoluble material with 10 % trichloroacetic acid and extraction of DNA with 0.1 M NaOH. The precipitates were collected on Whatman GF/B filters, which were cut up and counted in a scintillation counter.
Measurement of cGMP cGMP concentrations in Al0 VSMCs were assayed as previously described by Kariya et al. [21] . At YC-1 in a 50 mM Tris/HCl buffer, pH 7.4. Incubations were carried out at 37°C for 10 min with 50 4ul (1 mg/ml) of enzyme preparation, and terminated by adding 0.5 M HCl and 1 mM imidazole. The tubes were then heated to 100°C for 3 min in an electric heating block and cooled in an ice-bath. The supernatant was applied to a neutral alumina column to isolate cGMP for radioassay of 32P and 3H. Protein was determined by using Bradford reagent (Bio-Rad) [24] .
Determination of cGMP-specffic phosphodiesterase activity The supernatant fraction of AIO VSMC lysate was used for cGMP-specific phosphodiesterase determination [25, 26] . The crude cytosolic enzyme (8.4 mg/ml) was incubated with cGMP (1O ,tM, containing 0.1 ,uCi of [3H]cGMP) and compound in a final volume of 0.4 ml (buffer was 50 mM Tris/HCl, 5 mM MgCl2, pH 7.4). After 30 min at 25°C, the samples were heated to 100°C for 1 min before cooling. Snake (Ophiophagus hannah) venom (0.1 ml; 1 mg/ml) was then added for 30 min to convert the 5'-GMP into the uncharged nucleoside, guanosine. Anionexchange resin (Dowex 1; 1 ml) was added to bind all of the unconverted cGMP. After centrifugation, an aliquot (0.5 ml) of the supernatant was removed for quantification in a liquidscintillation counter.
Cell-cycle analysis
To estimate the proportions of cells in different phases of the cell cycle, cellular DNA contents were measured by flow cytometry as described by March et al. [27] . Briefly, cells (2 x 106 cells/ml) were fixed in 70 % ethanol (in PBS) in ice for 30 min and then resuspended in PBS containing 40 ,ug/ml propidium iodide and 0.1 mg/ml RNAase (Boehringer, Mannheim, Germany). After 30 min at 37°C, 2 x 104 cells were analysed on a FACstar cytofluorimeter (Becton-Dickinson, San Jose, CA, U.S.A.) exciting at 488 nm and sensing at 585 nm.
Cell growth
To determine the effect of YC-l on cell growth, cells (2.5 x 103/ well) were cultured for 48 h in FCS-free medium to induce quiescence. They were then cultured for 6 days in medium supplemented with 10% FCS, in the presence or absence of YC-1. Culture medium and YC-1 were changed daily and cell numbers were determined by dissociation of adherent cells with trypsin and counting in a haemocytometer. (Figure 2) . The inhibitory effect of YC-1 was Table 2 Effects of IBMX and YC-1 on VSMC cGMP-specifMc phosphodiesterase activity Cell extracts were incubated with various concentrations of IBMX or YC-1 for 10 min and then assayed for enzyme activity as described in the Materials and methods section. Values are presented as means + S.E.M. (n = 4). * P < 0.05, ** P < 0.001, compared with basal activity.
Data analysis

Concn.
Phosphodiesterase activity Addition (#M) [15, 32] . A major therapeutic aim is to inhibit VSMC proliferation without interfering with endothelial-cell proliferation [30, 31] . YC-1 (1-1I00 ,M), which selectively inhibits AO0 VSMC proliferation without affecting endothelial-cell proliferation, might therefore be expected to prevent or inhibit the progress of vascular diseases. Yang et al. [33] have reported that donors of NO inhibit the proliferation of cultures of bovine foetal aortic, human umbilical-vein and mouse lymph-nodevessel endothelial cells, but Ziche et al. [34] reported that exogenous NO enhances the proliferation ofthis cell type cultured from bovine coronary post-capillary venules. The exact reason for the discrepancy between these results is unclear, but it may be due to differences in the cell lines and experimental conditions used.
Effects of YC-1 on cGMP formation and guanylate cyclase acftvation The dose of YC-1 required to inhibit FCS-induced proliferation was similar to that necessary for cGMP formation (Figure 3 ).
The site of action ofYC-I-induced cGMP formation was clarified by determining the activities of guanylate cyclase and cGMPspecific phosphodiesterase. As shown in Table 1 , dose-dependent increases in soluble guanylate cyclase activity were observed in YC-I and SNP-treated VSMCs. cGMP-specific phosphodiesterase activity was inhibited by IBMX, whereas YC-1 (100 ,uM) had no effect on this enzyme activity in AIO VSMCs (Table 2 ). These results demonstrate that YC-1 is an activator of soluble guanylate cyclase in VSMCs. Figure 4 (b) it caused significant potentiation of the anti-proliferative activity of YC-1, particularly at low concentrations of the latter. These results verify that guanylate cyclase was the effector of YC-1, and the anti-proliferative effect of YC-l was mediated by cGMP. cGMP has been reported to inhibit the proliferation of VSMCs [32, 37] , but the molecular mechanisms of this anti-proliferative action remain to be clarified. Inhibition of proliferation of cGMP-elevating agents (e.g. SNP and 3-morpholinosydonimine) at concentrations higher than those required for vasorelaxation [15, 38, 39] was also observed in this study. Reasons for this discrepancy may include instability of these agents [40] and binding to serum [41] . However, inhibition of proliferation by YC-1 at concentrations of 1-100,uM was Figure 5 ). DNA synthesis increased slowly, reached its maximum within 16 h, and declined soon after. The GI-phase can be confined to the first 8 h, the S-phase between 10 and 18 h, and the G2/M-phase between 20 and 26 h. To clarify the mode of antiproliferative action of YC-1, the relationship between the time of addition of YC-1 and its inhibitory action on FCS-induced DNA synthesis was examined. As shown in Figure 5 , YC-I still inhibited FCS-induced DNA synthesis even when added 10-18 h after the addition of FCS. This result implies that YC-1 inhibits FCSinduced proliferation by inhibiting progression from the G1-to the S-phase of the cell cycle. Furthermore, the present flowcytometric results demonstrate that YC-1 inhibits progression from the G1/S-phase of the cell cycle. After a 48 h exposure to serum-free medium, most VSMCs remained in the GO-phase of the cell cycle (Figure 6a ). After replacement ofserum-free medium with DMEM containing 10 % FCS, the emergence of cells into and through the S-phase was observed by flow cytometry using quantitative DNA staining with propidium iodide (Figure 6b ). The majority of cycling cells were found to progress through the S-phase approximately 18 h after serum repletion (Figure 6b ). YC-I -treated cells showed an acute blockage of cell cycle progression occurring at the G1/S-phase; no increase in DNA content was observed in cells stimulated by serum in the presence of YC-1 (100,uM) (Figure 6c ). This result is consistent with cGMP-elevating vasodilators exerting their anti-proliferative action by inhibiting progression from the G1-to the S-phase of the cell cycle [15, 21, 32] . Our results are also consistent with previous work [7, 11, 32] showing that elevated cGMP concentrations at a latter stage of the G1-phase of the cell cycle would be necessary to inhibit proliferation. Figure 7 InhIbfflon of VSMC growth by YC-1
VSMCs were seeded on 12-well plates (density was 2.5 x 103/well) and counted in Trypan Blue at subsequent time points. Dimethyl sulphoxide (0) or YC-1 (100 gUM) (M) was added and the mixture incubated for 6 days in medium supplemented with 10% FCS. Results represent means + S.E.M. of three separate experiments, each in quadruplicate, and are expressed as the fold increase in ceH number relative to that on day 0 of the experiment. The difference between each of the growth curves in the presence of YC-1 and control was significant (* P < 0.05, ** P < 0.01) by analysis of variance.
2.8(± 0.2) x103 in control wells and 3.0(±0.3) x 103 in YC-l (100 ,uM)-treated wells. Furthermore, no significant release of lactate dehydrogenase was observed in this experiment, again indicating that, in short-term incubations, even higher concentrations of YC-1 did not induce cell damage. (c) Less than 1 % of the cells treated with YC-1 (100 ,uM) for 24 h stained with Trypan Blue.
In conclusion, this study demonstrates that YC-1 inhibits VSMC proliferation via the guanylate cyclase/cGMP pathway. and by inhibiting progression from the G1-to the S-phase of the cell cycle. The anti-proliferative effect of YC-1 is unlikely to cause cell toxicity, therefore it may have potential as a therapeutic agent for the prevention of vascular diseases.
